Stockscreener 앱 받기
0.6634
4.16%
0.0268
시간 외 거래:
.66
-0.0034
-0.51%
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Atossa Therapeutics announces issuance of U.S. patent - MSN
Atossa Therapeutics (ATOS) Secures New U.S. Patent for (Z)-endoxifen Formulations - GuruFocus
Atossa Therapeutics secures new patent for breast cancer treatment - Investing.com
Atossa Therapeutics (ATOS) Secures Patent for New (Z)-endoxifen Formulation | ATOS Stock News - GuruFocus
Atossa Therapeutics secures new patent for breast cancer treatment By Investing.com - Investing.com India
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio - The Manila Times
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio | ATOS Stock News - GuruFocus
New Patent Strengthens Atossa's Breast Cancer Drug Portfolio: What This Means for Treatment Innovation - Stock Titan
Ascendiant Capital Markets Issues Positive Forecast for Atossa Therapeutics (NASDAQ:ATOS) Stock Price - Defense World
Atossa Therapeutics (ATOS) Partners with Nona Biosciences to Adv - GuruFocus
Nona Biosciences and Atossa Therapeutics Partner to Discover Nex - GuruFocus
Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - The Manila Times
Revolutionary Breast Cancer Treatment Alliance: Next-Gen Antibody Platform Powers New Research Initiative - Stock Titan
Atossa Therapeutics (NASDAQ:ATOS) & Pharming Group (OTCMKTS:PHGUF) Critical Comparison - Defense World
Atossa Therapeutics says Intas Pharmaceuticals Filed Petition For Post Grant Review Against Co- SEC Filing - marketscreener.com
Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress - MSN
Charles Schwab Investment Management Inc. Lowers Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Monday - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock By Investing.com - Investing.com Canada
Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst - Defense World
Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock - Investing.com India
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Yahoo Finance
Atossa Therapeutics (NASDAQ:ATOS) Earns Buy Rating from HC Wainwright - Defense World
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Yahoo
Atossa Therapeutics Inc (ATOS) Q4 2024 Earnings Call Highlights: - GuruFocus
Atossa Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Atossa Therapeutics’ Strategic Focus on Z-endoxifen for Breast Cancer Drives Buy Rating - TipRanks
Earnings call transcript: Atossa Genetics Q4 2024 beats EPS forecast - Investing.com
Atossa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Atossa Therapeutics Inc Reports Q4 EPS of -$0.06, Aligning with Estimates; Revenue Remains at $0 Million - GuruFocus
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
Earnings Scheduled For March 25, 2025 - Benzinga
Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Tuesday - Defense World
Atossa Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Atossa Therapeutics to Host Conference Call for Q4 and Full-Year 2024 Financial Results on March 25, 2025 - Nasdaq
Atossa Therapeutics Earnings: Key Q4 and 2024 Results Coming March 25How to Listen Live - StockTitan
Atossa Therapeutics (NASDAQ:ATOS) Given “Buy” Rating at HC Wainwright - The AM Reporter
HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock hits 52-week low at $0.7 amid market challenges - Investing.com Australia
Atossa Genetics stock hits 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa
Nothing is Better Than Atossa Therapeutics Inc (ATOS) stock at the moment - SETE News
Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - TradingView
Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen - TipRanks
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - The Manila Times
Breakthrough: New Breast Cancer Drug Shows 3x Better Survival Rate Than Standard Treatment - StockTitan
Atossa targets metastatic breast cancer with (Z)-endoxifen - Investing.com
Atossa Genetics stock hits 52-week low at $0.72 - Investing.com
Atossa Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com India
0.92%
자본화:
|
볼륨(24시간):